Editor’s highlights from Future Oncology – September 2020

Written by Louis Gautier, Future Science Group

Future Oncology

In this latest instalment of his regular monthly column, Louis Gautier, Commissioning Editor of Future Oncology, exclusively shares some of his top picks from the recent journal issues, which we have made freely available for you, Oncology Central members! Check out Louis’ highlights below: Biosimilars in oncology: key role of nurses in patient education Biosimilars are a recent advent in oncology, with the first biosimilar being approved in the US in September of 2017. Due to the coronavirus pandemic that has lingered throughout 2020, financial pressures and the economic burden of current cancer treatments mean biosimilars could represent a hugely important...

To view this content, please register now for access

It's completely free